Exploiting interleukin 6 in multicentric Castleman's disease

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 910-912

  Bower, Mark ^a   Stebbing, Justin ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PLACEBO; RITUXIMAB; SILTUXIMAB; MONOCLONAL ANTIBODY;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B LYMPHOCYTE; CANCER CELL LINE; CELL DIFFERENTIATION; CELL MEMBRANE TRANSPORT; DISEASE ASSOCIATION; DRUG EFFICACY; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; NOTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GIANT LYMPH NODE HYPERPLASIA; MALE;

ANTIBODIES, MONOCLONAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE;

EID: 84905044666     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70333-X     Document Type: Note

References (10)

1. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1276-1280.
2. Fajgenbaum DC, van Rhee F, Nabel CS HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014, 123:2924-2933.
3. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014, published online July 18. http://dx.doi.org/10.1016/S1470-2045(14)70319-5.
4. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000, 96:2069-2073.
5. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002, 20:304-311.
6. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999, 93:4034-4043.
7. Stone K, Woods E, Szmania SM, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One 2013, 8:e54610.
8. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated nulticentric Castleman's disease. J Clin Oncol 2011, 29:2481-2486.
9. Bower M, Pria AD, Coyle C, Nelson M, Naresh K Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. J Acquir Immune Defic Syndr 2014, 65:e80-e82.
10. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011, 117:6977-6986.